Josh Mandel-Brehm - Oct 10, 2024 Form 3 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role
Chief Executive Officer, Director
Signature
By: /s/ Thomas Danielski, as Attorney-in-Fact
Stock symbol
CAMP
Transactions as of
Oct 10, 2024
Transactions value $
$0
Form type
3
Date filed
10/10/2024, 09:06 PM
Previous filing
Oct 7, 2024
Next filing
Oct 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAMP Common Stock 272K Oct 10, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAMP Series B Preferred Stock Oct 10, 2024 Common Stock 605 Direct F1
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 25K $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 2.27K $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 30.7K $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 2.84K $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 1.42K $2.12 Direct F2
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 66.9K $5.50 Direct F3
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 342K $8.41 Direct F4
holding CAMP Stock Option (Right to Buy) Oct 10, 2024 Common Stock 44.6K $9.08 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a 11.2158-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Preferred Stock has no expiration date.
F2 This option is fully vested and exercisable as of the date hereof.
F3 This option had a vesting start date of March 1, 2022 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.
F4 This option had a vesting start date of September 1, 2022 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.
F5 This option had a vesting start date of March 7, 2024 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date.

Remarks:

Exhibit 24 - Power of Attorney